IL-7 is known to promote the survival of tumor-specific T cells [211], and preclinical studies have shown that genetically modification to enhance IL-7 signaling, either through secretion or receptor overexpression, can significantly boost their anti-tumor efficacy [212]. This evidence concerns the gene IL7 and neoplasm.